Amgen's osteoporosis drug Prolia recommended by NICE

In final draft guidance published Wednesday, the National Institute for Health and Clinical Excellence recommended that postmenopausal women at increased risk of osteoporotic fractures should be treated with Amgen's Prolia (denosumab) if other treatments are unsuitable. Carole Longson, Health Technology Evaluation Centre Director at NICE, noted that the agency "felt that there was good quality evidence to show that denosumab is a useful addition to the treatment options available for women who can't have oral bisphosphonates."
Reference Articles
Final draft guidance recommends osteoporosis treatment as a new option for women at increased risk of fractures - (NICE)
UK's NICE approves Amgen's Prolia for osteoporosis - (The Wall Street Journal)
**Published by "First Word"